BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Todd Berard Sells 8,902 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) CMO Todd Berard sold 8,902 shares of the company's stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $22.66, for a total transaction of $201,719.32. Following the sale, the chief marketing officer now directly owns 135,956 shares in the company, valued at $3,080,762.96. This trade represents a 6.15 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Todd Berard also recently made the following trade(s):

• On Tuesday, March 11th, Todd Berard sold 1,577 shares of BioLife Solutions stock. The stock was sold at an average price of $25.00, for a total value of $39,425.00.
• On Monday, March 3rd, Todd Berard sold 424 shares of BioLife Solutions stock. The stock was sold at an average price of $25.46, for a total value of $10,795.04.
• On Wednesday, February 12th, Todd Berard sold 102 shares of BioLife Solutions stock. The shares were sold at an average price of $26.54, for a total transaction of $2,707.08.
• On Monday, January 6th, Todd Berard sold 343 shares of BioLife Solutions stock. The stock was sold at an average price of $27.02, for a total transaction of $9,267.86.

BioLife Solutions Stock Down 5.9 %

Shares of BioLife Solutions stock traded down $1.30 on Tuesday, hitting $20.64. The company had a trading volume of 785,746 shares, compared to its average volume of 367,480. BioLife Solutions, Inc. has a 1 year low of $14.84 and a 1 year high of $29.55. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The stock has a 50 day moving average of $25.43 and a 200-day moving average of $25.41. The stock has a market capitalization of $970.08 million, a price-to-earnings ratio of -19.47 and a beta of 1.93.

Remove Ads

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last issued its quarterly earnings data on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.32. The business had revenue of $22.71 million for the quarter, compared to analysts' expectations of $21.73 million. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. During the same period last year, the business earned ($0.21) EPS. As a group, sell-side analysts forecast that BioLife Solutions, Inc. will post -0.3 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently weighed in on BLFS. StockNews.com upgraded shares of BioLife Solutions from a "sell" rating to a "hold" rating in a report on Tuesday. HC Wainwright upped their price target on BioLife Solutions from $27.00 to $30.00 and gave the stock a "buy" rating in a research note on Thursday, March 6th. Benchmark reissued a "buy" rating and issued a $30.00 price objective on shares of BioLife Solutions in a research note on Thursday, December 19th. Northland Securities boosted their price objective on BioLife Solutions from $28.00 to $31.00 and gave the company an "outperform" rating in a report on Wednesday, January 8th. Finally, KeyCorp increased their target price on BioLife Solutions from $30.00 to $33.00 and gave the stock an "overweight" rating in a report on Friday, December 13th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $31.17.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC bought a new position in shares of BioLife Solutions during the 4th quarter worth approximately $26,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of BioLife Solutions in the fourth quarter valued at approximately $31,000. 1620 Investment Advisors Inc. increased its position in shares of BioLife Solutions by 41.7% during the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider's stock valued at $60,000 after acquiring an additional 675 shares during the last quarter. Smartleaf Asset Management LLC lifted its holdings in BioLife Solutions by 27.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 4,469 shares of the medical equipment provider's stock worth $117,000 after acquiring an additional 950 shares during the period. Finally, KLP Kapitalforvaltning AS purchased a new position in BioLife Solutions in the fourth quarter worth $171,000. 93.24% of the stock is currently owned by hedge funds and other institutional investors.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.